HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Long-Acting Insulin (Insulin, Long Acting)

Subscribe to New Research on Long-Acting Insulin

Insulin formulation containing substance which delays or retards time period of the absorption of insulin.

Also Known As:

Insulin, Long Acting; Mixtard; Protamine Zinc Insulin; Insulin, Long-Acting; Insulin Novo Monotard; Insulin, Lente; Insulin, Lente, Monocomponent; Insulin, Monotard; Insulin, Protamine Zinc; Insulin, Protamine Zinc, Beef-Pork; Insulin, Semilente; Protophan; Ultralente Insulin; Insulin, Ultralente; Lente Insulin; Long Acting Insulin; Monotard Insulin; Monotard, Insulin Novo; Novo Monotard, Insulin; Semilente Insulin; Zinc Insulin, Protamine

Networked: 250 relevant articles (10 outcomes, 35 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bolli, Geremia B: 4 articles (06/2011 - 01/2006)
2.	Dippel, F-W: 2 articles (12/2015 - 03/2009)
3.	Qayyum, Rehan: 2 articles (04/2011 - 10/2008)
4.	Davies, M J: 2 articles (12/2009 - 08/2008)
5.	Alemzadeh, Ramin: 2 articles (08/2009 - 05/2005)
6.	Smith, Steven A: 2 articles (03/2008 - 01/2005)
7.	de Boer, H: 2 articles (09/2006 - 03/2004)
8.	Jansen, M: 2 articles (09/2006 - 03/2004)
9.	Verschoor, L: 2 articles (09/2006 - 03/2004)
10.	Schwartz, Sherwyn: 2 articles (01/2006 - 11/2004)

Related Diseases

1.	Hypoglycemia (Reactive Hypoglycemia) 05/01/2008 - "The use of these long-acting insulin analogues appears to be associated with a reduced incidence of hypoglycemia, especially at night. " 07/01/2004 - "The use of this long-acting insulin analogue appears to be associated with a reduced incidence of hypoglycemia, especially at night. " 01/01/2014 - "Clinical trials have shown that this ultra long-acting insulin analogue administered in a flexible dosage treatment, reached a good glycaemic control with no increase on hypoglycemia risk. " 01/01/2007 - "Randomized clinical trials suggest that the long-acting insulin analogs are associated with a lower risk for nocturnal hypoglycemia than neutral protamine Hagedorn without sacrificing glycemic control." 04/01/1997 - "To study this, groups of rats were injected with approximately 25 U/kg ultralente insulin daily at 1700 for 8 days to maintain hypoglycemia. "
2.	Diabetes Mellitus 01/01/2001 - "Efficacy of protamine zinc insulin for treatment of diabetes mellitus in cats." 10/01/1969 - "[Comparative efficacy of long-acting insulin preparations in diabetes mellitus]." 03/01/2009 - "The purpose of this study was to review studies reporting on quality of life and treatment satisfaction of patients with diabetes mellitus being treated with long-acting insulin analogues. " 06/01/1937 - "Control of Diabetes Mellitus with Protamine Zinc Insulin in Surgery : (Based Upon a Study of 25 Cases)." 01/01/2010 - "Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes."
3.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/01/1984 - "The aim was to study the effect of dose on subcutaneous absorption of semisynthetic human Lente-type insulin (Monotard HM) in IDDM patients. " 03/01/2008 - "Type 1 diabetes mellitus treatment includes plain substitution and individualization for short-acting plus long-acting insulin according to the physician's assistance, besides regular practice of physical activities and diet orientations. " 01/01/2008 - "Intermediate acting versus long acting insulin for type 1 diabetes mellitus." 06/01/1995 - "Twelve cats with insulin-dependent diabetes mellitus were treated with lente insulin. " 09/01/2011 - "Long-acting insulin treatments with varying clinical benefits are currently available for patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). "
4.	Weight Gain 09/01/2006 - "The aim of this study was to investigate whether a regimen free of long-acting insulin can provide long-term glycaemic control without causing weight gain. " 03/01/2004 - "To test the concept that regain of glycaemic control can be achieved without causing weight gain, using a regimen free of long-acting insulin. " 11/01/1984 - "Peripherally administered, long acting insulin stimulates weight gain and food intake. " 01/01/1983 - "Rats were made to overeat and gain weight (about 50 g) by long-acting protamine zinc insulin (PZI) treatment. " 10/01/1979 - "Effect of protamine zinc insulin on feed intake and weight gain in broiler chicks."
5.	Body Weight (Weight, Body) 02/01/1985 - "After an overnight fast 0.4 U of intermediate acting insulin (Monotard MC/NOVO INDUSTRIES) per kg body weight were injected subcutaneously. " 01/01/1978 - "Daily administration of 2 U protamine zinc insulin (PZI)/100 g body weight to diabetic rats returned these measurements to normal levels. " 09/01/2007 - "STZ+insulin-treated group C diabetic rats were additionally treated with subcutaneous injections of lente insulin (0.5 U/kg body weight) daily from Day 10 to Day 30 of our 40-day study period. " 09/01/1983 - "Rats were given daily injections of protamine-zinc insulin (PZI) that increased food intake and body weight. " 01/01/1982 - "Lean rats were then given daily injections of protamine zinc insulin at 3 doses: 0.25, 1.25, and 4.0 U.100 g body wt-1.day-1 for 3 wk. Obese rats received identical amounts as corresponding lean controls independent of body weights. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	glargine (insulin glargine)
3.	Glucose (Dextrose)
4.	insulin detemir (Levemir)
5.	Metformin (Glucophage)
6.	Hypoglycemic Agents (Hypoglycemics)
7.	NPH Insulin
8.	insulin LISPRO (Humalog)
9.	Blood Glucose (Blood Sugar)
10.	Zinc

Related Therapies and Procedures

1.	Subcutaneous Injections
2.	Carbohydrate-Restricted Diet (Low Carbohydrate Diet)
3.	Communication Aids for Disabled (TDD)
4.	Injections
5.	Intraperitoneal Injections